Denali Therapeutics (DNLI) News Today $21.93 +0.26 (+1.20%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside PotentialJanuary 17 at 8:13 PM | msn.comDenali Therapeutics' (DNLI) Outperform Rating Reiterated at William BlairJanuary 17 at 2:32 AM | americanbankingnews.comDenali Therapeutics Inc. (NASDAQ:DNLI) Stock Holdings Increased by JPMorgan Chase & Co.JPMorgan Chase & Co. raised its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 6.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 235,386 shares of the company's stock after buying an additionaJanuary 16 at 3:12 AM | marketbeat.comWhy Is Denali Therapeutics Stock Trading Higher On Wednesday?January 15 at 3:01 PM | benzinga.comDenali Therapeutics (NASDAQ:DNLI) Trading 9.8% Higher - Time to Buy?Denali Therapeutics (NASDAQ:DNLI) Trading 9.8% Higher - Should You Buy?January 15 at 12:26 PM | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Receives Outperform Rating from William BlairWilliam Blair reissued an "outperform" rating on shares of Denali Therapeutics in a research note on Wednesday.January 15 at 8:18 AM | marketbeat.comBank of America Securities Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)January 15 at 2:40 AM | markets.businessinsider.comDenali Therapeutics sees cash runway into 2028January 13, 2025 | msn.comAnalysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) Target Price at $38.91January 13, 2025 | americanbankingnews.comDenali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been given an average rating of "Moderate Buy" by the fourteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendJanuary 10, 2025 | marketbeat.comDenali: Despite ALS Primary Endpoint Failure, Possible Path Forward RemainsJanuary 9, 2025 | seekingalpha.comWhy biotech startup Tenvie sees promise in drugs from founders' old companyJanuary 9, 2025 | bizjournals.comWhat is HC Wainwright's Forecast for DNLI FY2026 Earnings?Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Analysts at HC Wainwright boosted their FY2026 EPS estimates for shares of Denali Therapeutics in a research note issued to investors on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($January 9, 2025 | marketbeat.comSteve E. Krognes Sells 3,339 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) StockJanuary 9, 2025 | insidertrades.comDenali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Baird R WJanuary 9, 2025 | americanbankingnews.comHC Wainwright Issues Pessimistic Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock PriceJanuary 9, 2025 | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) Coverage Initiated by Analysts at Robert W. BairdJanuary 9, 2025 | americanbankingnews.comFY2028 Earnings Forecast for DNLI Issued By HC WainwrightJanuary 9, 2025 | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) Shares Gap Down After Analyst DowngradeJanuary 9, 2025 | americanbankingnews.comInsider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 3,339 Shares of StockDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) Director Steve E. Krognes sold 3,339 shares of the firm's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total value of $69,484.59. Following the sale, the director now directly owns 25,757 shares of the company's stock, valued at $536,003.17. This trade represents a 11.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.January 8, 2025 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Insider Carole Ho Sells 12,255 SharesDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) insider Carole Ho sold 12,255 shares of Denali Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $247,796.10. Following the transaction, the insider now directly owns 178,580 shares in the company, valued at $3,610,887.60. This trade represents a 6.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.January 8, 2025 | marketbeat.comRyan J. Watts Sells 29,266 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) StockDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) CEO Ryan J. Watts sold 29,266 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $591,758.52. Following the sale, the chief executive officer now owns 260,721 shares of the company's stock, valued at approximately $5,271,778.62. This represents a 10.09 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.January 8, 2025 | marketbeat.comDenali Therapeutics announces U.S. FDA BTD granted for tividenofuspJanuary 8, 2025 | markets.businessinsider.comDenali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)January 8, 2025 | markets.businessinsider.comDenali Therapeutics (NASDAQ:DNLI) Trading Up 3.1% - What's Next?Denali Therapeutics (NASDAQ:DNLI) Stock Price Up 3.1% - Here's WhyJanuary 8, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for DNLI FY2028 Earnings?Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at HC Wainwright lifted their FY2028 earnings estimates for shares of Denali Therapeutics in a research note issued to investors on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will post eJanuary 8, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Upgraded to "Strong-Buy" at Baird R WBaird R W upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Tuesday.January 8, 2025 | marketbeat.comDenali Therapeutics price target lowered to $32 from $35 at BTIGJanuary 8, 2025 | markets.businessinsider.comBofA trims Denali Therapeutics price target to $30, says weakness an opportunityJanuary 7, 2025 | markets.businessinsider.comDenali Therapeutics (DNLI) Gets a Buy from J.P. MorganJanuary 7, 2025 | markets.businessinsider.comBaird Initiates Coverage of Denali Therapeutics (DNLI) with Outperform RecommendationJanuary 7, 2025 | msn.comJPMorgan Chase & Co. Lowers Denali Therapeutics (NASDAQ:DNLI) Price Target to $24.00JPMorgan Chase & Co. lowered their target price on Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating for the company in a research note on Tuesday.January 7, 2025 | marketbeat.comDenali Therapeutics Says ALS Trial Didn't Meet EndpointsJanuary 7, 2025 | marketwatch.comDenali Reverses Its Fortunes With 'Too Early' Miss In ALS TreatmentJanuary 7, 2025 | yahoo.comDenali Therapeutics initiated with an Outperform at BairdJanuary 7, 2025 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Denali Therapeutics (DNLI)January 7, 2025 | markets.businessinsider.comDenali Therapeutics (NASDAQ:DNLI) Shares Gap Down on Analyst DowngradeDenali Therapeutics (NASDAQ:DNLI) Shares Gap Down on Analyst DowngradeJanuary 7, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Price Target Cut to $87.00 by Analysts at HC WainwrightHC Wainwright dropped their target price on shares of Denali Therapeutics from $90.00 to $87.00 and set a "buy" rating for the company in a research report on Tuesday.January 7, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Earns Outperform Rating from Analysts at Robert W. BairdRobert W. Baird started coverage on Denali Therapeutics in a research note on Tuesday. They issued an "outperform" rating and a $31.00 price target on the stock.January 7, 2025 | marketbeat.comDenali Therapeutics ALS drug fails in mid-stage trialJanuary 6, 2025 | reuters.comDenali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialJanuary 6, 2025 | globenewswire.comDenali Therapeutics (NASDAQ:DNLI) Shares Down 4.1% After Insider SellingDenali Therapeutics (NASDAQ:DNLI) Shares Down 4.1% on Insider SellingJanuary 6, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Denali Therapeutics (DNLI) with Outperform RecommendationJanuary 4, 2025 | msn.comInsider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 3,080 Shares of StockJanuary 4, 2025 | insidertrades.comDenali Therapeutics initiated with an Outperform at William BlairJanuary 3, 2025 | markets.businessinsider.comDenali Therapeutics Inc. (NASDAQ:DNLI) Director Sells $64,402.80 in StockDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) Director Vicki L. Sato sold 3,080 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the sale, the director now owns 107,976 shares of the company's stock, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.January 3, 2025 | marketbeat.comWilliam Blair Initiates Coverage on Denali Therapeutics (NASDAQ:DNLI)William Blair initiated coverage on shares of Denali Therapeutics in a research report on Friday. They set an "outperform" rating on the stock.January 3, 2025 | marketbeat.comPrincipal Financial Group Inc. Increases Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Principal Financial Group Inc. raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 13.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,238,476 shares of the company's stock after buying an additional 149,939 shDecember 24, 2024 | marketbeat.comGeode Capital Management LLC Sells 27,061 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)Geode Capital Management LLC lowered its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 0.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,955,477 shares of the company's stock afteDecember 20, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Stock Holdings Lifted by Barclays PLCBarclays PLC increased its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 101.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 255,883 shares of the company's stock after buying an additional 128,823 shares during the period. BarclaysDecember 19, 2024 | marketbeat.com Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address DNLI Media Mentions By Week DNLI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNLI News Sentiment▼0.450.68▲Average Medical News Sentiment DNLI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNLI Articles This Week▼125▲DNLI Articles Average Week Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Qiagen News Today Vaxcyte News Today Ascendis Pharma A/S News Today Roivant Sciences News Today Revolution Medicines News Today Lantheus News Today Blueprint Medicines News Today BridgeBio Pharma News Today Legend Biotech News Today Elanco Animal Health News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNLI) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNLI Stock Alerts